Sehhoon Park, Steve Olsen, Bo Mi Ku, Min-Sang Lee, Hyun-Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon-La Choi, Myung-Ju Ahn
BACKGROUND: Because of the growing number of actionable biomarkers in non-small cell lung cancer (NSCLC), sufficient tissue availability for testing is becoming a greater challenge. Liquid biopsy offers a potential solution by complementing standard tissue-based methods. In this study, the authors analyzed the concordance of actionable genomic alterations sequenced from circulating tumor DNA (ctDNA; Guardant360) and tissue (Oncomine Focus Assay). METHODS: From September 2015 to May 2018, 421 paired plasma and tissue samples from patients with advanced NSCLC who had previously undergone tissue testing by standard methods were collected...
April 7, 2021: Cancer
Sarah D Tait, Yi Ren, Cushanta C Horton, Sachiko M Oshima, Samantha M Thomas, Sherry Wright, Awanya Caesar, Jennifer K Plichta, E Shelley Hwang, Rachel A Greenup, Laura H Rosenberger, Gayle D DiLalla, Carolyn S Menendez, Lisa Tolnitch, Terry Hyslop, Debi Nelson, Oluwadamilola M Fayanju
BACKGROUND: The North Carolina Breast and Cervical Cancer Control Program (NC BCCCP) provides breast cancer screening services to underserved women to mitigate disparities in access to care. The authors sought to characterize this understudied population. METHODS: Women 21 years old or older who underwent their first breast cancer screen through NC BCCCP from 2008 to 2018 were included. Demographic factors associated with the timeline of care and odds of a breast cancer diagnosis were identified with negative binomial and logistic regression, respectively...
April 7, 2021: Cancer
Kristy Kummerow Broman, Tasha Hughes, Lesly Dossett, James Sun, Dennis Kirichenko, Michael J Carr, Avinash Sharma, Edmund K Bartlett, Amanda A G Nijhuis, John F Thompson, Tina J Hieken, Lisa Kottschade, Jennifer Downs, David E Gyorki, Emma Stahlie, Alexander van Akkooi, David W Ollila, Jill Frank, Yun Song, Giorgos Karakousis, Marc Moncrieff, Jenny Nobes, John Vetto, Dale Han, Jeffrey M Farma, Jeremiah L Deneve, Martin D Fleming, Matthew C Perez, Michael C Lowe, Roger Olofsson Bagge, Jan Mattsson, Ann Y Lee, Russell S Berman, Harvey Chai, Hidde M Kroon, Juri Teras, Roland M Teras, Norma E Farrow, Georgia Beasley, Jane Yuet Ching Hui, Lukas Been, Schelto Kruijff, Youngchul Kim, Syeda Mahrukh Hussnain Naqvi, Amod A Sarnaik, Vernon K Sondak, Jonathan S Zager
BACKGROUND: For patients with sentinel lymph node (SLN)-positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease-specific survival (DSS) with active surveillance using nodal ultrasound versus completion lymph node dissection (CLND). Adoption and outcomes of active surveillance in clinical practice and in adjuvant therapy recipients are unknown. METHODS: In a retrospective cohort of SLN-positive adults treated at 21 institutions in Australia, Europe, and the United States from June 2017 to November 2019, the authors evaluated the impact of active surveillance and adjuvant therapy on all-site recurrence-free survival (RFS), isolated nodal RFS, distant metastasis-free survival (DMFS), and DSS using Kaplan-Meier curves and Cox proportional hazard models...
April 7, 2021: Cancer
Stephanie Stangl, Sebastian Rauch, Jürgen Rauh, Martin Meyer, Jacqueline Müller-Nordhorn, Manfred Wildner, Achim Wöckel, Peter U Heuschmann
BACKGROUND: Breast cancer (BC), which is most common in elderly women, requires a multidisciplinary and continuous approach to care. With demographic changes, the number of patients with chronic diseases such as BC will increase. This trend will especially hit rural areas, where the majority of the elderly live, in terms of comprehensive health care. METHODS: Accessibility to several cancer facilities in Bavaria, Germany, was analyzed with a geographic information system...
April 7, 2021: Cancer
Chelsea Anderson, Deborah K Mayer, Hazel B Nichols
BACKGROUND: Improvements in cancer survival mean that an increasing number of survivors may live long enough beyond their initial cancer to be diagnosed with additional independent primary cancers. The proportion of newly diagnosed cancers that are second- or higher-order primaries and how this proportion has changed over the past several decades were examined. METHODS: Data from the Surveillance, Epidemiology, and End Results (SEER) program were used to identify incident malignant primaries diagnosed between 1975 and 2017...
April 6, 2021: Cancer
Kiyomi Morita, Hagop M Kantarjian, Koji Sasaki, Ghayas C Issa, Nitin Jain, Marina Konopleva, Nicholas J Short, Koichi Takahashi, Courtney D DiNardo, Tapan M Kadia, Guillermo Garcia-Manero, Naval Daver, Guillermo Montalban Bravo, Jorge E Cortes, Farhad Ravandi, Elias Jabbour
BACKGROUND: Dasatinib monotherapy has demonstrated modest clinical activity in chronic myeloid leukemia in lymphoid blastic phase (CML-LBP). The outcome of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) has dramatically improved with hyperfractionated cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (hyper-CVAD) in combination with tyrosine kinase inhibitors (TKIs). METHODS: The authors reviewed 85 patients (23 with CML-LBP and 62 with newly diagnosed Ph-positive ALL) who received hyper-CVAD plus dasatinib...
April 6, 2021: Cancer
Kenneth J Caldwell, Amit Budhraja, Joseph T Opferman, Ching-Hon Pui, Jeffery M Klco, Jeffrey E Rubnitz
No abstract text is available yet for this article.
April 6, 2021: Cancer
Danielle S Bitterman, Ming-Hui Chen, Jing Wu, Andrew A Renshaw, Marian Loffredo, Philip W Kantoff, Eric J Small, Anthony V D'Amico
BACKGROUND: Although both PSA nadir (PSAn) and testosterone levels at PSA failure are known prognostic factors in men undergoing radiation therapy (RT) and androgen deprivation therapy (ADT) for unfavorable-risk prostate cancer (PC), it is unclear whether their prognostic significance is independent or overlapping. METHODS: Seventy-five men treated with RT with or without 6 months of ADT for unfavorable-risk nonmetastatic PC enrolled in 2 prospective clinical trials between 1986 and 2001 formed the study cohort...
April 6, 2021: Cancer
Yufeng Chen, Ellen T Chang, Qing Liu, Yonglin Cai, Zhe Zhang, Guomin Chen, Qi-Hong Huang, Shang-Hang Xie, Su-Mei Cao, Wei-Hua Jia, Yuming Zheng, Yancheng Li, Longde Lin, Ingemar Ernberg, Dongming Wang, Weihong Chen, Ruimei Feng, Guangwu Huang, Yi-Xin Zeng, Hans-Olov Adami, Weimin Ye
BACKGROUND: The potential role of occupational exposures in the development of nasopharyngeal carcinoma (NPC) remains unclear, particularly in high-incidence areas. METHODS: The authors conducted a population-based case-control study, consisting of 2514 incident NPC cases and 2586 randomly selected population controls, in southern China from 2010 to 2014. Occupational history and other covariates were self-reported using a questionnaire. Multivariate logistic regression was used to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for the risk of NPC associated with occupational exposures...
April 6, 2021: Cancer
Travis P Schrank, Nicholas Lenze, Lee P Landess, Alan Hoyle, Joel Parker, Asim Lal, Siddharth Sheth, Bhishamjit S Chera, Samip N Patel, Trevor G Hackman, M Ben Major, Natalia Issaeva, Wendell G Yarbrough
BACKGROUND: Human papillomavirus-positive (HPV+) squamous cell carcinoma of the oropharynx (OPSCC) is the most prevalent HPV-associated malignancy in the United States. Favorable treatment outcomes have led to increased interest in treatment de-escalation to reduce treatment morbidity as well as the development of prognostic markers to identify appropriately low-risk patients. Intratumoral genomic heterogeneity and copy number alteration burden have been demonstrated to be predictive of poor outcomes in many other cancers; therefore, we sought to determine whether intratumor heterogeneity and genomic instability are associated with poor outcomes in HPV+ OPSCC...
April 5, 2021: Cancer
Koji Sasaki, Farhad Ravandi, Tapan M Kadia, Courtney D DiNardo, Nicholas J Short, Gautam Borthakur, Elias Jabbour, Hagop M Kantarjian
BACKGROUND: Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of acute myeloid leukemia (AML). METHODS: The authors identified 29,107 patients who were diagnosed with de novo AML between 1980 and 2017 in the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Patients were categorized into 5 age groups (ages birth to 14, 15-39, 40-59, 60-69, and ≥70 years) and 4 calendar periods (1980-1989, 1990-1999, 2000-2009, and 2010-2017)...
April 5, 2021: Cancer
Giovana R Thomas
No abstract text is available yet for this article.
April 2, 2021: Cancer
Rohith S Voora, Nikhil V Kotha, Abhishek Kumar, Edmund M Qiao, Alexander S Qian, Bharat A Panuganti, Matthew P Banegas, Philip A Weissbrod, Tyler F Stewart, Brent S Rose, Ryan K Orosco
BACKGROUND: Black patients with laryngeal squamous cell carcinoma (LSCC) historically have inferior outcomes in comparison with White patients. The authors investigated these racial disparities within the Veterans Health Administration (VHA), an equal-access system, and within the Surveillance, Epidemiology, and End Results (SEER) program, which is representative of the US hybrid-payer system. METHODS: Patients with invasive (T1 or greater) LSCC were included from SEER (2004-2015) and the VHA (2000-2017)...
April 2, 2021: Cancer
Jeffrey I Traylor, Lana D Christiano, Bita Esmaeli, Matthew M Hanasono, Peirong Yu, Dima Suki, Wen Zhang, Shaan M Raza, Ehab Y Hanna, Franco DeMonte
BACKGROUND: Orbital exenteration (OE) is an ablative procedure used in the management of malignancies of the orbit of either primary or secondary origin. Publications evaluating this procedure have suffered from small patient numbers, heterogeneity of pathologies, and poor patient follow-up. The purpose of this study was to assess patient outcomes in a large cohort of patients undergoing OE at a tertiary cancer center. METHODS: A retrospective review was conducted of 180 consecutive patients who underwent OE at the authors' institution...
April 2, 2021: Cancer
Shabbir M H Alibhai, Henriette Breunis, Aaron R Hansen, Richard Gregg, Padraig Warde, Narhari Timilshina, George Tomlinson, Anthony M Joshua, Sebastien Hotte, Neil Fleshner, Urban Emmenegger
BACKGROUND: Because multiple treatments are available for metastatic castrate-resistant prostate cancer (mCRPC) and most patients are elderly, the prediction of toxicity risk is important. The Cancer and Aging Research Group (CARG) tool predicts chemotherapy toxicity in older adults with mixed solid tumors, but has not been validated in mCRPC. In this study, its ability to predict toxicity risk with docetaxel chemotherapy (CHEMO) was validated, and its utility was examined in predicting toxicity risk with abiraterone or enzalutamide (A/E) among older adults with mCRPC...
April 2, 2021: Cancer
Hari S Iyer, Scarlett L Gomez, Jarvis T Chen, Quoc-Dien Trinh, Timothy R Rebbeck
BACKGROUND: Reducing disparities in men with prostate cancer (PCa) that may be caused by racial and socioeconomic differences is a major public health priority. Few reports have studied whether these disparities have changed over time. METHODS: Men diagnosed with PCa from January 1, 2000 to December 31, 2015 were identified from the Massachusetts and Pennsylvania cancer registries. All-cause mortality and PCa and cardiovascular cause-specific mortality were assessed...
April 2, 2021: Cancer
Giovanni Corso, Patrick Maisonneuve, Paolo Veronesi
No abstract text is available yet for this article.
April 1, 2021: Cancer
Kathryn R Tringale, Elizabeth R Berger, Alexandra S Heerdt, Lior Z Braunstein
No abstract text is available yet for this article.
April 1, 2021: Cancer
Francesca Palandri, Mario Tiribelli, Massimo Breccia, Daniela Bartoletti, Elena M Elli, Giulia Benevolo, Bruno Martino, Francesco Cavazzini, Alessia Tieghi, Alessandra Iurlo, Elisabetta Abruzzese, Novella Pugliese, Gianni Binotto, Giovanni Caocci, Giuseppe Auteri, Daniele Cattaneo, Malgorzata M Trawinska, Rossella Stella, Luigi Scaffidi, Nicola Polverelli, Giorgia Micucci, Elena Masselli, Monica Crugnola, Costanza Bosi, Florian H Heidel, Roberto Latagliata, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto M Lemoli, Michele Cavo, Nicola Vianelli, Massimiliano Bonifacio, Giuseppe A Palumbo
BACKGROUND: After ruxolitinib discontinuation, the outcome of patients with myelofibrosis (MF) is poor with scarce therapeutic possibilities. METHODS: The authors performed a subanalysis of an observational, retrospective study (RUX-MF) that included 703 MF patients treated with ruxolitinib to investigate 1) the frequency and reasons for ruxolitinib rechallenge, 2) its therapeutic effects, and 3) its impact on overall survival. RESULTS: A total of 219 patients (31...
April 1, 2021: Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"